Bajaj Healthcare Credit Rating Upgraded, FY26 Revenue Rises

Bajaj Healthcare's long-term credit rating has been upgraded to 'IND A' from 'IND A-' by India Ratings and Research (Ind-Ra), with a stable outlook. The short-term rating was also improved to 'IND A1' from 'IND A2+'.

Revenue for FY26 grew 12.6% to ₹611 crore from ₹542.6 crore in FY25. EBITDA increased to ₹104.8 crore from ₹82.4 crore, with margins expanding to 17.2% from 15.2%. The company reported ₹165.6 crore revenue in 1QFY27.

Reader Takeaway: Rating upgrade and revenue growth are positive; working capital cycle and regulatory compliance are key watch points.

What just happened

India Ratings upgraded Bajaj Healthcare’s long-term credit rating to 'IND A' and short-term to 'IND A1'. The company's revenue rose to ₹611 crore in FY26, up from ₹542.6 crore in FY25. EBITDA margins improved to 17.2% in FY26.

Why this matters

The rating upgrade signals improved financial health and debt-servicing capabilities. Revenue growth and margin expansion indicate strengthening operational performance, potentially leading to better investor confidence and access to finance.

The backstory

Bajaj Healthcare has been working on improving its financial metrics. The company has reduced its debt facility size to ₹282 crore from ₹332.62 crore. This is supported by strategic investments in R&D and manufacturing.

What changes now

The upgraded rating may lead to better borrowing terms and a stronger credit profile. Investments in a new R&D center and a peptide API facility are expected to drive future growth and market expansion.

Risks to watch

Key concerns include a potentially elongated working capital cycle, which can impact cash flow. Additionally, regulatory risks associated with manufacturing facilities could lead to delays in product approvals or market access.

Peer comparison

While specific peer data is not provided in the filing, credit rating upgrades generally position a company more favorably compared to peers with lower ratings, potentially enhancing its competitive standing in securing new business.

Context metrics (time-bound)

• FY26 Revenue: ₹611 crore (up from ₹542.6 crore in FY25)
• FY26 EBITDA Margin: 17.2% (up from 15.2% in FY25)
• FY26 Gross Interest Coverage: 4.7x (up from 3.0x in FY25)
• Debt Facility Size: Reduced to ₹282 crore
• Planned Capital Investment: ₹50 crore

What to track next

Investors should monitor the company's progress on its R&D center and peptide API facility. Continued improvement in working capital management and successful navigation of regulatory requirements will be crucial.